Zecotek Photonics Inc. (TSX VENTURE: ZMS) (FRANKFURT: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the Company has closed on the first tranche of the private placement, previously announced on November 7, 2016, by selling 1,000,000 units of the Company at a price of $0.30 per unit for gross proceeds of $300,000.
Each unit of the Company consists of one common share and one common share purchase warrant. Each warrant of the first tranche entitles the holder to acquire one common share at an exercise price of $0.43 per common share at any time on or before November 18, 2018.
The Company paid finder’s fees on the tranche consisting of cash fees totalling $21,000 and issued 70,000 finder’s warrants. Each finder’s warrant entitles the Warrantholder to acquire one unit (the “Unit”) at a price of Cdn$0.30 per Unit. Each Unit consists of one Common Share in the capital of the Company and one half of a share purchase warrant (the “Unit Warrant”). Each whole Unit Warrant shall entitle the Warrantholder to acquire one Common Share at a price of Cdn$0.43 per Common Share until November 18, 2018.
All securities issued are subject to a four-month hold period expiring on March 19, 2017.
Net proceeds from the funds raised will be used for general working capital purposes including the manufacture of products and strengthening and maintaining the Company’s IP portfolio. All shares and warrants are subject to a four-month hold period.
Zecotek Photonics Inc (TSX VENTURE: ZMS) (FRANKFURT: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances, the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.
For Additional Information Please Contact:
SmallCapPower.com (SCP) is the industry’s most trusted resource for small cap stocks, offering unprecedented access to the research and tools you need to help uncover the next big thing.
Except for the historical information presented herein, matters discussed in this document contain forward- looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Ubika Research and www.smallcappower.com (are both divisions of Ubika Corporation), and are not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this report. For making specific investment decisions, readers should seek their own advice.
Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
For full disclosure please visit Here >>
For additional information contact:
Mark Thorburn- Manager, Media Relations